论文部分内容阅读
目的探讨脑卒中后抑郁患者经安脑丸与艾司西酞普兰联合治疗的临床应用价值。方法选取我院在2013年2月至2015年2月间收治的86例脑卒中后抑郁患者的临床资料,将患者随机分为两组,各43例。两组患者均接受常规治疗,对照组在常规治疗基础上采用艾司西酞普兰治疗,观察组在常规治疗基础上给予安脑丸与艾司西酞普兰联合治疗,比较两组患者的治疗效果与不良反应发生情况。结果 1观察组有41例患者治疗有效,总有效率为95.35%。对照组有34例患者治疗有效,总有效率为79.09%,两组对比有统计学意义(P<0.05)。2观察组不良反应为2.33%,对照组不良反应发生率为4.66%,对比无统计学意义(P>0.05)。结论安脑丸与艾司西酞普兰联合应用在脑卒中后抑郁患者治疗中的应用价值较高,有利于改善患者的病情,对其神经恢复有促进作用,值得临床推广应用。
Objective To investigate the clinical value of the combined treatment of Ann Nao Wan and escitalopram in patients with post-stroke depression. Methods The clinical data of 86 post-stroke depression patients admitted from February 2013 to February 2015 in our hospital were selected. The patients were randomly divided into two groups of 43 patients. The two groups of patients received routine treatment, the control group on the basis of conventional treatment with escitalopram, the observation group was given conventional treatment based on the combination of escitalopram and escitalopram, the treatment effect was compared between the two groups And adverse reactions occurred. Results 1 The observation group of 41 patients with effective treatment, the total effective rate was 95.35%. The control group of 34 patients were treated effectively, the total effective rate was 79.09%, the two groups were statistically significant (P <0.05). The adverse reactions in the observation group were 2.33%, and the incidence of adverse reactions in the control group was 4.66%, with no significant difference (P> 0.05). Conclusion Combination of aspirin and escitalopram in patients with post-stroke depression in the treatment of higher value, help to improve the patient’s condition, the promotion of nerve recovery, it is worth promoting the clinical application.